BMS secures expanded FDA approval for Camzyos to reduce need for SRT
Bristol Myers Squibb (BMS) has received the expanded US Food and Drug Administration (FDA) approval for Camzyos (mavacamten) to reduce patients’ need for septal reduction therapy (SRT). Camzyos